These data suggest that the xenograft breast tumor growth enhanced by resistin-stimulated ADSCs was potentially associated with the increased expression of CXCL5 and mesenchymal markers, such as Slug, along with the activation of ERK pathway. Here, CXCL5 is linked to breast neoplasm.